Fukuda, Masaki http://orcid.org/0000-0001-9207-4434
Hattori, Junko
Ohkubo, Rika
Watanabe, Asuka
Maekawa, Shinichiroh
Funding for this research was provided by:
MSD K.K.
Article History
Accepted: 10 June 2024
First Online: 27 June 2024
Declarations
:
: The PMS and publication of this article were funded by MSD K.K., Tokyo, Japan.
: Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, and Shinichiroh Maekawa are employees of MSD K.K., Tokyo, Japan.
: This survey was carried out in accordance with Good Post-Marketing Study Practice for Drugs as specified by the Ministry of Health, Labour and Welfare in Japan. The research protocol was approved by the Japan Conference of Clinical Research Institution Review Board (approval date 21 January, 2021).
: Informed consent was not required for this PMS in accordance with Good Post-Marketing Study Practice in Japan. Informed consent was obtained voluntarily at some facilities. All facilities agreed with the use of the survey data under a contract/agreement with MSD K.K., Tokyo, Japan.
: Not applicable.
: The data sharing policy, including restrictions, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA is available at . Requests for access to the study data can be submitted through the Engage Zone site or via e-mail to the Data Access mailbox (dataaccess@merck.com).
: Not applicable.
: All authors met ICMJE authorship criteria; their specific contributions are as follows: conceptualization: all authors; data curation: AW, SM; formal analysis: AW, SM; investigation: all authors; methodology: AW, SM; project administration: MF; supervision: MF; validation: AW, SM; visualization: MF, JH, RO; writing: original draft: MF, JH, RO; writing: review and editing: all authors. All authors approved the final version of this manuscript and agree to be accountable for all aspects of the work.